Literature DB >> 12724692

Visual complications of proton beam therapy for clival chordoma.

J Bowyer1, S Natha, I Marsh, P Foy.   

Abstract

PURPOSE: Combining maximal surgical resection with high-dose proton radiation therapy is reported to be currently the best management of patients with clival chordoma.
METHOD: Since 1991, four consecutive patients from our institution with this tumour have been referred for postoperative proton beam radiotherapy. RESULT: We have experienced an unusually high complication rate (50%) of delayed radiation optic neuropathy. This has resulted in profound, bilateral visual loss at 1 and 2 years postproton beam treatment.
CONCLUSION: It has served as a reminder that proton beam therapy is not an innocuous treatment option and this devastating complication should be taken into account when discussing the management of clivus chordoma. We postulate whether the optic apparatus is particularly sensitive to proton vs photon damage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12724692     DOI: 10.1038/sj.eye.6700339

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  3 in total

Review 1.  Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma.

Authors:  Brian J Jian; Orin G Bloch; Isaac Yang; Seunggu J Han; Derick Aranda; Tarik Tihan; Andrew T Parsa
Journal:  J Neurooncol       Date:  2009-12-02       Impact factor: 4.130

Review 2.  Chordoma dedifferentiation after proton beam therapy: a case report and review of the literature.

Authors:  Joseph Frankl; Cassi Grotepas; Baldassare Stea; G Michael Lemole; Alexander Chiu; Rihan Khan
Journal:  J Med Case Rep       Date:  2016-10-12

3.  iASPP overexpression is associated with clinical outcome in spinal chordoma and influences cellular proliferation, invasion, and sensitivity to cisplatin in vitro.

Authors:  Yunlong Ma; Bin Zhu; Xiaoguang Liu; Zhongjun Liu; Liang Jiang; Feng Wei; Miao Yu; Fengliang Wu; Hua Zhou; Nanfang Xu; Xiao Liu; Lei Yong; Yongqiang Wang; Peng Wang; Chen Liang; Guanping He
Journal:  Oncotarget       Date:  2017-08-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.